Clinical Trials Browser

Completed × Neoplasm, Residual × Azacitidine × Clear all

NCT04712942 2023-08-21

Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

Phase 2 Completed

Myelodysplastic Syndromes, Neoplasm, Residual

NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

Phase 1 Completed

MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual